Policy issues related to expanded newborn screening: a review of three genetic/metabolic disorders

Policy, Politics & Nursing Practice
Heddy Bishop Hubbard

Abstract

In 2005, a federal advisory committee recommended that the number of disorders in state newborn screening programs be expanded from 9 to 29. In view of this recommendation, state leaders will need to make cogent decisions regarding the expanse of their state newborn screening programs. They must consider several factors, including the costs and outcomes of the screening program. The expense of the initial screening test can be misleading because it does not include the cost of the entire program (testing, tracking, notifying, retesting, confirmatory testing, and follow-up). Also, outcomes such as false positive findings can be costly to newborn screening programs, result in additional testing for infants, and lead to parental concern and worry. This article examines some of the policy issues related to newborn screening and specifically focuses on three disorders recommended for newborn screening, cystic fibrosis (CF), medium-chain acyl CoA dehydrogenase Deficiency (MCADD), and beta-ketothiolase (BKT).

References

Mar 1, 1991·The American Review of Respiratory Disease·E Kerem, A Lynch
Dec 22, 1999·Journal of Inherited Metabolic Disease·K MonastiriM N Guediche
Mar 16, 2000·The American Journal of Medicine·B T Thach
Jul 13, 2000·Archives of Pediatrics & Adolescent Medicine·C Kwon, P M Farrell
Mar 17, 2001·Genetics in Medicine : Official Journal of the American College of Medical Genetics·UNKNOWN American College of Medical Genetics/American Society of Human Genetics Test and Technology Transfer Committee Working Group
Apr 18, 2001·American Journal of Preventive Medicine·R P HarrisUNKNOWN Methods Work Group, Third US Preventive Services Task Force
Aug 23, 2001·Archives of Disease in Childhood. Fetal and Neonatal Edition·K CarpenterB Wilcken
Jan 5, 2002·BMJ : British Medical Journal·James V Leonard, Carol Dezateux
Jun 6, 2003·The New England Journal of Medicine·Bridget WilckenKevin Carpenter
Jul 3, 2003·The Journal of Pediatrics·Don S LeePhilip M Farrell
Aug 12, 2003·Pediatric Pulmonology·Philip M FarrellMark L Splaingard
Aug 15, 2003·American Journal of Respiratory and Critical Care Medicine·Philip M FarrellMark L Splaingard
Nov 20, 2003·JAMA : the Journal of the American Medical Association·Susan E WaisbrenHarvey L Levy
Nov 25, 2003·Paediatric Respiratory Reviews·Evelyn P Parsons, Donald M Bradley
Dec 6, 2003·The Journal of Pediatrics·Michael H Farrell, Philip M Farrell
Mar 30, 2004·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·T FukaoT Ariga
Apr 17, 2004·Clinical and Experimental Immunology·T AsanoN Kondo
Aug 28, 2004·Primary Care·Shawn E McCandless
Jul 6, 2005·Clinical and Experimental Immunology·A K KnightC Cunningham-Rundles
Aug 11, 2005·Cost Effectiveness and Resource Allocation : C/E·Neil SimpsonHeather Lannin
Sep 27, 2005·The Annals of Thoracic Surgery·Johannes M AlbesMartin Hartrumpf
Sep 27, 2005·The Journal of Pediatrics·Erika J SimsUNKNOWN UK CF Database Steering Committee
Oct 7, 2005·Pediatric Pulmonology·David S ArmstrongKeith Grimwood
Jan 19, 2006·Public Health Reports·Jennifer KraszewskiSara Rosenbaum
May 9, 2006·MCN. the American Journal of Maternal Child Nursing·Joanna K Spahis, Nancy R Bowers
Jun 1, 2006·Pediatrics·UNKNOWN American College of Medical Genetics Newborn Screening Expert Group
Sep 5, 2006·Pediatrics·Celia I KayeLloyd-Puryear Michele A
Nov 15, 2006·Journal of Sports Sciences·H Okubo, M Hubbard

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.